Journal of Skin and Stem Cell

Published by: Kowsar

Determination of Whether Vitiligo is a Contraindication to Interferon Therapy in Chronic Hepatitis C

Seyed Moayed Alavian 1 , 2 , *
Author Information
1 Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, Iran
2 Middle East Liver Disease Center, Tehran, Iran
Article information
  • Journal of Skin and Stem Cell: May 25, 2014, 1 (1); e16639
  • Published Online: May 15, 2014
  • Article Type: Editorial
  • Received: December 7, 2013
  • Revised: December 15, 2013
  • Accepted: February 22, 2014
  • DOI: 10.17795/jssc16639

To Cite: Alavian S M. Determination of Whether Vitiligo is a Contraindication to Interferon Therapy in Chronic Hepatitis C, J Skin Stem Cell. 2014 ; 1(1):e16639. doi: 10.17795/jssc16639.

Copyright © 2014, Skin and Stem Cell Journal. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
Acknowledgements
Footnotes
References
  • 1. Alavian SM. New globally faces of hepatitis B and C in the world. Gastro Hepat FBB. 2011; 4(4): 171-4
  • 2. Ataei B, Shirani K, Alavian SM, Ataie M. Evaluation of Knowledge and Practice of Hairdressers in Women's Beauty Salons in Isfahan About Hepatitis B, Hepatitis C, and AIDS in 2010 and 2011. Hepat Mon. 2013; 13(3)[DOI][PubMed]
  • 3. Alavian SM. We Need a New National Approach to Control Hepatitis C: It is Becoming too Late. Hepat Mon. 2008; 8(3): 165-9
  • 4. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007; 13(17): 2436-41[PubMed]
  • 5. Alavian SM, Adibi P, Zali MR. Hepatitis C virus in Iran: Epidemiology of an emerging infection. Arch Iran Med. 2005; 8: 84-90
  • 6. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005; 5(9): 558-67[PubMed]
  • 7. Alberti A, Benvegnu L. Management of hepatitis C. J Hepatol. 2003; 38 Suppl 1-18[PubMed]
  • 8. Ebrahimi Daryani N, Alavian SM, Somi MH, Torabi-Nami M. Hepatitis C and Why the Treatment is Needed Now? The Summary Report From the Cross-Border Symposium of the 5th Tehran Hepatitis Congress May 2013. Hepat Mon. 2013; 13(11)[DOI]
  • 9. Maddrey WC. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients. Semin Liver Dis. 1999; 19 Suppl 1: 67-75[PubMed]
  • 10. Namazee N, Sali S, Asadi S, Shafiei M, Behnava B, Alavian SM. Real response to therapy in chronic hepatitis C virus patients: a study from iran. Hepat Mon. 2012; 12(9)[DOI][PubMed]
  • 11. Prummel MF, Laurberg P. Interferon-alpha and autoimmune thyroid disease. Thyroid. 2003; 13(6): 547-51[DOI][PubMed]
  • 12. Conrad B. Potential mechanisms of interferon-alpha induced autoimmunity. Autoimmunity. 2003; 36(8): 519-23[PubMed]
  • 13. Gilhar A, Zelickson B, Ulman Y, Etzioni A. In vivo destruction of melanocytes by the IgG fraction of serum from patients with vitiligo. J Invest Dermatol. 1995; 105(5): 683-6[PubMed]
  • 14. van den Wijngaard R, Wankowicz-Kalinska A, Le Poole C, Tigges B, Westerhof W, Das P. Local immune response in skin of generalized vitiligo patients. Destruction of melanocytes is associated with the prominent presence of CLA+ T cells at the perilesional site. Lab Invest. 2000; 80(8): 1299-309[PubMed]
  • 15. Akbayir N, Gokdemir G, Mansur T, Sokmen M, Gunduz S, Alkim C, et al. Is there any relationship between hepatitis C virus and vitiligo? J Clin Gastroenterol. 2004; 38(9): 815-7[PubMed]
  • 16. Arican O, Sasmaz S, Kokoglu OF. Role of hepatitis B and C viruses in the etiopathogenesis of vitiligo. J Dermatol. 2004; 31(6): 506-7[PubMed]
  • 17. Alavian SM, Shokohi A. [Vitiligo is a complication of interferon therapy in chronic hepatitis B]. Iran J Dermatol. 2002; 5(3): 45-9
  • 18. Oiso N, Sato M, Kawada A. Vitiligo after combination therapy of pegylated interferon-alpha-2a, ribavirin and vitamin D in a patient with chronic hepatitis C. J Dermatol. 2013; 40(9): 772-3[DOI][PubMed]
  • 19. Hamadah I, Binamer Y, Sanai FM, Abdo AA, Alajlan A. Interferon-induced vitiligo in hepatitis C patients: a case series. Int J Dermatol. 2010; 49(7): 829-33[DOI][PubMed]
  • 20. Taffaro M, Pyrsopoulos N, Cedron H, Cacayorin E, Weppler D, Moon J, et al. Vitiligo improvement in a hepatitis C patient after treatment with PEG-interferon alpha-2a and ribavirin: a case report. Dig Dis Sci. 2007; 52(12): 3435-7[DOI][PubMed]
  • 21. Arya V, Bansal M, Girard L, Arya S, Valluri A. Vitiligo at Injection Site of PEG-IFN-alpha 2a in Two Patients with Chronic Hepatitis C: Case Report and Literature Review. Case Rep Dermatol. 2010; 2(2): 156-64[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments